A cross-sectional survey on VEXAS syndrome: insights from a global expert panel
Clinical Rheumatology · 2025-10 · 44 (10) · 4385-4393
DOI: 10.1007/s10067-025-07617-3 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 09.08.2025. Verfasst von Syed B Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au. Hauptthemen laut MEDLINE: Genetic Diseases, X-Linked, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flinders University.
Abstract (Originalsprache)
Background
Vacuolization, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is recently described, for which the diagnosis and management lack official guidelines.
Aims
To assess the diagnostic capabilities and disease management of VEXAS syndrome among physicians in the global context.
Methods
An electronic survey was sent to clinicians with expertise in VEXAS syndrome between January and February 2025 to gather real-life data on the management of VEXAS.
Results
Seventy-four clinicians completed the survey from Europe ( n = 51, 68.9%), North America ( n = 9, 12.2%), Australasia ( n = 6, 8.1%), Asia ( n = 6, 8.1%), Africa ( n = 1, 1.4%), and South America ( n = 1, 1.4%), mostly being hematologists ( n = 24, 32.4%) and rheumatologists ( n = 24, 32.4%). Majority of the clinicians were managing between 1 and 4 ( n = 40, 54.1%) and 5 and 9 patients ( n = 17, 23%) with VEXAS syndrome, with regular clinic review, typically under 7-weekly intervals ( n = 44, 59.5%). UBA1 mutation testing was available for 76% of physicians and next-generation sequencing (NGS) of the entire gene was most common ( n = 24, 32.9%) with a turnaround time within 12 weeks. C-reactive protein (CRP) was selected by over half of the clinicians ( n = 35, 55.4%) as a marker of disease relapse. Treatment with corticosteroids at 1 mg/kg ( n = 48, 64.9%) was the most common initial dosing and upfront systemic immunomodulatory treatment was added by more than half of clinicians ( n = 39, 52.7%). The most frequent treatments of choice ( n = 66) were Janus kinase inhibitors (JAKi) and IL-6 targeted monoclonal antibodies (both n = 21, 31.8%). Azacitidine was mostly used in patients with concomitant myelodysplastic syndrome (MDS) (69.9%). Only 29.6% indicated that allogeneic hematopoietic stem cell transplant (allo-HSCT) had been successfully completed in their department.
Conclusions
This is the first clinician survey on VEXAS syndrome, encompassing a global representation of multiple specialties on current disease management, highlighting several unmet needs (longitudinal follow-up, lack of on-label drugs, financial toxicity) actionable for future research. Keypoints • Globally, VEXAS syndrome is being increasingly recognized, and this survey demonstrates real-life physician practices. • The survey identified both hematologists and rheumatologists as the main care providers, amongst other specialties, identifying the need for a multidisciplinary approach in managing patients with VEXAS syndrome. • Diagnostic UBA1 testing was available for more than 75% clinicians with turnaround time < 12 weeks and C-reactive protein was selected as a useful marker of disease relapse. • Treatment modalities were heterogeneous, identifying the need for consensus guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au.
- School of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au.
- School of Medicine and Biomedical Sciences, University of Adelaide, Adelaide, South Australia, Australia. syed.ali@sa.gov.au.
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Förderung
- Flinders University
Zitieren
APA
Ali, S. B., & Gurnari, C. (2025). A cross-sectional survey on VEXAS syndrome: insights from a global expert panel. Clinical Rheumatology, 44(10), 4385-4393. https://doi.org/10.1007/s10067-025-07617-3
Vancouver
Ali SB, Gurnari C. A cross-sectional survey on VEXAS syndrome: insights from a global expert panel. Clinical Rheumatology. 2025;44(10):4385-4393. doi:10.1007/s10067-025-07617-3
BibTeX
@article{Ali2025,
author = {Ali, Syed B and Gurnari, Carmelo},
title = {A cross-sectional survey on VEXAS syndrome: insights from a global expert panel},
journal = {Clinical Rheumatology},
year = {2025},
volume = {44},
number = {10},
pages = {4385--4393},
doi = {10.1007/s10067-025-07617-3}
}
EUVIMED